Form 6-K Radiopharm Theranostics For: Jul 22

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of July 2026

 

Commission File Number: 001-41621

 

RADIOPHARM THERANOSTICS LIMITED

(Name of Registrant)

 

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐

 

 

 

RADIOPHARM THERANOSTICS LIMITED

 

EXPLANATORY NOTE

 

Radiopharm Theranostics Limited (the “Company”) published two announcements (the “Public Notice”) to the Australian Securities Exchange on July 22, 2026 titled:

 

“RAD Achieves Partial Response in Phase 1 Trial of RAD204”

“RAD Announces Positive Phase 2b Trial Results of RAD 101”

 

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

 

This Form 6-K, including the exhibits hereto, is incorporated by reference into the registration statement of the Company on Form F-3 (File No. 333-292178) and forms part thereof to the extent not superseded by documents or reports subsequently filed by the Company under the Securities Act of 1933 or the Securities Exchange Act of 1934. 

 

 

EXHIBITS

 

Exhibit Number		Description
99.1		RAD Achieves Partial Response in Phase 1 Trial of RAD204
99.2		RAD Announces Positive Phase 2b Trial Results of RAD 101

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	RADIOPHARM THERANOSTICS LIMITED
Date: July 22, 2026	By:	/s/ Nathan Jong
		Nathan Jong
		Company Secretary

 

 

ATTACHMENTS / EXHIBITS

RAD ACHIEVES PARTIAL RESPONSE IN PHASE 1 TRIAL OF RAD204

RAD ANNOUNCES POSITIVE PHASE 2B TRIAL RESULTS OF RAD 101

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Radiopharm reports partial response in RAD204 cancer drug trial
• GRUPO COMERCIAL CHEDRAUI, S.A.B. DE C.V. SECOND QUARTER 2026 RESULTS
• Radiopharm RAD101 meets Phase 2b endpoint for brain metastases